Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)—results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care

Autor: Asmis, T.R. ^*, Powell, E., Karapetis, C.S., Jonker, D.J., Tu, D., Jeffery, M., Pavlakis, N., Gibbs, P., Zhu, L., Dueck, D.-A., Whittom, R., Langer, C., O'Callaghan, C.J.

Publikováno v: In Annals of Oncology January 2011 22(1):118-126

Docetaxel and Gemcitabine administered on days 1 and 8 for metastatic non-small cell lung carcinoma (NSCLC): a phase II multicenter trial

Autor: Hirsh, Vera, Whittom, R., Desjardins, P., Laberge, F., Latreille, J., Samson, B., Langleben, A.

Publikováno v: In Lung Cancer 2004 46(1):113-118

Diet- and Lifestyle-Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance).

Autor: Cheng E; Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT.; Division of Research, Kaiser Permanente Northern California, Oakland, CA., Ou FS; Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN., Ma C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Spiegelman D; Department of Biostatistics, Yale School of Public Health, New Haven, CT.; Center on Methods for Implementation and Prevention Science, Yale School of Public Health, New Haven, CT., Zhang S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Zhou X; Department of Biostatistics, Yale School of Public Health, New Haven, CT.; Center on Methods for Implementation and Prevention Science, Yale School of Public Health, New Haven, CT., Bainter TM; Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN., Saltz LB; Memorial Sloan Kettering Cancer Center, New York, NY., Niedzwiecki D; Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC., Mayer RJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Whittom R; Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada., Hantel A; Loyola University, Stritch School of Medicine, Naperville, IL., Benson A; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL., Atienza D; Virginia Oncology Associates, Norfolk, VA., Messino M; Messino Cancer Centers, Asheville, NC., Kindler H; University of Chicago, Chicago, IL., Giovannucci EL; Department of Epidemiology, and Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA., Van Blarigan EL; Department of Epidemiology and Biostatistics, and Urology, University of California, San Francisco, CA., Brown JC; Cancer Metabolism Program, Pennington Biomedical Research Center, Baton Rouge, LA., Ng K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Gross CP; Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT.; Section of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT.; Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale Cancer Center, New Haven, CT., Meyerhardt JA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Fuchs CS; Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT.; Division of Hematology and Medical Oncology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT.; Yale Cancer Center, Smilow Cancer Hospital, New Haven, CT.; Hematology and Oncology Product Development, Genentech & Roche, South San Francisco, CA.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2022 Mar 01; Vol. 40 (7), pp. 740-751. Date of Electronic Publication: 2022 Jan 07.

Race, Income, and Survival in Stage III Colon Cancer: CALGB 89803 (Alliance).

Autor: Lee S; Yale School of Medicine, New Haven, CT, USA., Zhang S; Department of Medical Oncology, Dana-Farber/Partners CancerCare, Boston, MA, USA., Ma C; Department of Medical Oncology, Dana-Farber/Partners CancerCare, Boston, MA, USA., Ou FS; Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, USA., Wolfe EG; Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, USA., Ogino S; Department of Oncologic Pathology, Dana-Farber/Partners CancerCare and Harvard Medical School, Boston, MA, USA.; Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Niedzwiecki D; Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA., Saltz LB; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Mayer RJ; Department of Medical Oncology, Dana-Farber/Partners CancerCare, Boston, MA, USA., Mowat RB; Toledo Community Hospital Oncology Program, Toledo, OH, USA., Whittom R; Hôpital du Sacré-Coeur de Montréal, Montreal, Canada., Hantel A; Loyola University Stritch School of Medicine, Naperville, IL, USA., Benson A; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA., Atienza D; Virginia Oncology Associates, Norfolk, VA, USA., Messino M; Southeast Clinical Oncology Research Consortium, Mission Hospitals, Asheville, NC, USA., Kindler H; University of Chicago Comprehensive Cancer Center, Chicago, IL, USA., Venook A; University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA, USA., Gross CP; Yale School of Medicine, Department of Internal Medicine, New Haven, CT, USA., Irwin ML; Yale School of Public Health, New Haven, CT, USA., Meyerhardt JA; Department of Medical Oncology, Dana-Farber/Partners CancerCare, Boston, MA, USA., Fuchs CS; Yale School of Medicine, New Haven, CT, USA.; Yale Cancer Center, Smilow Cancer Hospital and Yale School of Medicine, New Haven, CT, USA.; Genentech, South San Francisco, CA, USA.

Publikováno v: JNCI cancer spectrum [JNCI Cancer Spectr] 2021 Apr 12; Vol. 5 (3). Date of Electronic Publication: 2021 Apr 12 (Print Publication: 2021).

Sugar-sweetened beverage intake and cancer recurrence and survival in CALGB 89803 (Alliance)

Autor: Venook, Alan, Fuchs, MA, Sato, K, Niedzwiecki, D, Ye, X, Saltz, LB, Mayer, RJ, Mowat, RB, Whittom, R, Hantel, A, Benson, A

Publikováno v: Venook, Alan; Fuchs, MA; Sato, K; Niedzwiecki, D; Ye, X; Saltz, LB; et al.(2014). Sugar-sweetened beverage intake and cancer recurrence and survival in CALGB 89803 (Alliance). UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/2zj2t5dm

Background: In colon cancer patients, obesity, sedentary lifestyle, and high dietary glycemic load have been associated with increased risk of cancer recurrence. High sugar-sweetened beverage intake has been associated with obesity, diabetes, and car

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::1d57df941c9ccb7c208dab2689c3a88b
http://www.escholarship.org/uc/item/2zj2t5dm